These results provide valuable insight into the synergistic mechanism between SNX-7081 and 2-FaraA that may provide an alternative treatment for CLL patients with p53 mutations, where options are currently limited [10]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.